Picture1.png
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
07 mars 2023 07h00 HE | Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track...
Cellectis Logo.png
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
06 mars 2023 16h30 HE | Cellectis Inc.
NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
Cellectis Logo.png
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
01 mars 2023 16h30 HE | Cellectis Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
Picture1.png
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
15 févr. 2023 07h00 HE | Autolus Therapeutics plc
LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Cellectis Logo.png
Monthly information on share capital and company voting rights
09 févr. 2023 16h30 HE | Cellectis Inc.
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Logo.png
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
07 févr. 2023 19h01 HE | Cellectis Inc.
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Logo.png
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
03 févr. 2023 09h33 HE | Cellectis Inc.
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Logo.png
Cellectis Announces Pricing of Follow-On Offering
03 févr. 2023 00h48 HE | Cellectis Inc.
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Logo.png
Cellectis Announces Launch of Follow-On Offering
02 févr. 2023 16h01 HE | Cellectis Inc.
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Logo.png
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
20 janv. 2023 16h30 HE | Cellectis Inc.
NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...